The Global Rapid Antigen Testing Market has emerged as a critical component of modern diagnostic medicine, fundamentally changing how infectious diseases are detected and managed. Rapid antigen tests (RATs) are immunochromatographic assays designed to detect the presence of specific viral or bacterial proteins (antigens) from respiratory specimens such as nasal swabs, throat swabs, or saliva. Unlike molecular tests (e.g., PCR) that amplify genetic material, antigen tests directly detect proteins from the pathogen, providing results in typically 15-30 minutes without the need for laboratory equipment or specialized personnel. While generally less sensitive than PCR, rapid antigen tests offer significant advantages in speed, cost, ease of use, and scalability, making them ideal for point-of-care settings, mass screening, and at-home use. The COVID-19 pandemic served as a massive catalyst for the rapid antigen testing market, validating the technology, scaling manufacturing capacity, and changing consumer behavior. As the world prepares for future pandemics and continues to manage endemic respiratory diseases (influenza, RSV, strep throat), the market for rapid antigen tests remains robust and is expected to continue its expansion.

According to the comprehensive report by WiseGuy Reports, the Global Rapid Antigen Testing Market was valued at approximately $2,400 million (USD 2.4 billion) in 2024. The market is projected to grow from $2,600 million in 2025 to $6.8 billion by 2035. This growth trajectory represents a compound annual growth rate (CAGR) of 9.9% during the forecast period from 2025 to 2035, underscoring the sustained demand for rapid diagnostic solutions beyond the acute phase of the COVID-19 pandemic.

Several interconnected factors are driving this steady growth. First and foremost is the increasing demand for rapid diagnostic solutions globally. The World Health Organization (WHO) has reported that quick diagnosis is essential for effective disease management, and rapid antigen tests have been proven to yield results in as little as 15-30 minutes. This is crucial in controlling the spread of diseases like COVID-19, where timely testing is directly linked to disease containment. The need for rapid testing is not limited to pandemics; endemic diseases such as influenza and streptococcal pharyngitis also benefit from quick diagnostic methods. Consequently, many governments are focusing on enhancing their healthcare infrastructure to include rapid testing capabilities, reflecting a significant shift towards decentralizing diagnostic testing.

Second, technological advancements in testing methods are promoting market growth. Innovations in testing methodologies, including the development of more accurate and user-friendly testing kits, enhance the reliability of results. The U.S. Food and Drug Administration (FDA) has approved various rapid antigen test kits that utilize novel technologies known for their improved sensitivity and specificity. The increase in patent filings for new testing methods indicates a strong trend toward R&D investments in this area, leading to a broader range of innovative products. Enhanced technology leads to higher adoption rates among healthcare providers globally, indicating that continuous improvements are pivotal in driving market expansion.

Third, government initiatives and funding have created a favorable environment for market growth. Many countries allocated funds and resources to develop rapid testing capabilities during the COVID-19 pandemic and have continued to support diagnostic infrastructure. The Centers for Disease Control and Prevention (CDC) has highlighted that government-driven initiatives have enabled affordable testing options, thereby increasing overall testing rates. These strategic investments in public health infrastructure not only bolster the rapid antigen testing market but also prepare healthcare systems for future disease outbreaks.

The rising incidence of infectious diseases is a fourth driver. The WHO has indicated a steady increase in infectious disease cases across multiple regions due to urbanization, climate change, and evolving pathogens. Tuberculosis affects approximately 10 million people annually. With early detection playing a crucial role in disease management, the demand for rapid antigen tests is expected to increase substantially. Healthcare professionals and governments recognize that early testing can lead to quicker treatment and better health outcomes.

The market is characterized by a competitive landscape involving major diagnostic companies, including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, BD (Becton, Dickinson and Company), bioMérieux, Quidel Corporation, Thermo Fisher Scientific, Danaher Corporation (Cepheid), and PerkinElmer . These companies are engaged in strategic partnerships, product launches, and capacity expansions. The report notes that in March 2025, Abbott Laboratories announced a strategic partnership to expand global manufacturing and distribution of rapid antigen tests. In November 2024, bioMérieux unveiled a next-generation rapid antigen test platform designed to deliver faster results with higher sensitivity. In June 2024, Roche Diagnostics announced a major contract win to supply rapid antigen testing kits to a large European health system.

Regionally, North America leads the market, driven by a robust healthcare infrastructure and increasing investments in rapid testing solutions. Europe follows closely, exhibiting steady expansion as countries invest in robust healthcare responses. The Asia-Pacific region is predicted to witness the highest growth rate, driven by increasing healthcare expenditure and a growing emphasis on early disease detection.